To assess the efficacy and safety of mirabegron in the treatment of neurogenic detrusor overactivity.
This prospective, multicenter, randomized, double-blind, placebo-controlled study was conducted in three tertiary centers, and included 78 patients suffering from spinal cord injury or multiple sclerosis.